Registration is open for a workshop on July 30 and 31, 2018, organized by the National Academies of Sciences, Engineering, and Medicine’s, Board on Chemical Sciences and Technology and sponsored by the U.S. Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA).
This workshop will discuss the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics, such as enzymes, monoclonal antibodies, and vaccines. The workshop will discuss specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical, and drug product development. The workshop will address these challenges broadly across the biologics domain but to focus particularly on drug categories of greatest FDA and industrial interest, such as monoclonal antibodies.
Featuring presentations, panel discussions, and breakout sessions—this workshop will bring together experts in the production of biologically-derived pharmaceuticals and provides a rare opportunity for industry leaders and academics to have deep discussions with leadership from the FDA and BARDA. This meeting is open to the public and aims to have a variety of perspectives represented.
Register Now to Attend In-person
When: Monday, Jul. 30 - 12:00 pm
Tuesday, Jul. 31 9:00 pm
Web: Visit Website